<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 REPORTING REQUIREMENTS
FORM 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 19, 2000
------------------------------
KING PHARMACEUTICALS, INC.
-------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Tennessee 0--24425 54-1684963
-------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
501 Fifth Street, Bristol, Tennessee 37620
-------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (423) 989-8000
----------------------------
Not Applicable
-------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
<PAGE> 2
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 5. OTHER EVENTS.
On October 19, 2000, King Pharmaceuticals, Inc., a Tennessee corporation,
filed a Prospectus Supplement dated October 17, 2000, pursuant to Rule 424(b)(5)
related to its registration statement no. 333-95181. The Prospectus Supplement
incorporated by reference Supplementary Consolidated Financial Statements
including a report thereon by PricewaterhouseCoopers LLP. These Supplementary
Consolidated Financial Statements and accompanying Management's Discussion and
Analysis of Financial Condition and Results of Operations are included as an
exhibit hereto.
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Description
------- -----------
<S> <C>
23(a) Consent of PricewaterhouseCoopers LLP
23(b) Consent of Ernst & Young LLP
99(a) Management's Discussion and Analysis of Financial Condition and
Results of Operations.
99(b) Supplementary Consolidated Financial Statements
</TABLE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KING PHARMACEUTICALS, INC.
Date: October 19, 2000
By: /s/ James R. Lattanzi
------------------------
James R. Lattanzi
Chief Financial Officer
